Evidence map›Paper›PMID 39536083›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Parallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome.

Alissandra L Hillis, Tigist Tamir, Grace E Perry, John M Asara, Jared L Johnson, Tomer M Yaron, Lewis C Cantley, Forest M White, Alex Toker

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Parallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alissandra L Hillis *Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.ORCID 0000-0002-6667-1291
Tigist Tamir *Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0002-8194-8754
Grace E PerryDepartment of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.ORCID 0000-0002-0404-9237
John M AsaraMass Spectrometry Core, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.ORCID 0000-0001-7450-2589
Jared L JohnsonDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115.
Tomer M YaronDepartment of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021.ORCID 0000-0001-6574-7314
Lewis C CantleyDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115.ORCID 0000-0002-1298-7653
Forest M WhiteKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0002-1545-1651
Alex TokerDepartment of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6M
The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7M
Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
The MIT Superfund Research Program: A Systems Approach for the Protection of Human Health from Hazardous ChemicalsP42ES027707 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Bevin P. Engelward · 2017 to 2026
$22.2M
Role of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2M
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in CancerR35CA253097 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Alex Toker · 2020 to 2026
$6.9M
Regulation of oxidative stress signaling by tyrosine phosphorylation of antioxidant enzymesK99GM152834 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TAMIR, TIGIST Y · 2023 to 2024
$175k
NCI NIH HHS P01 CA117969NCI NIH HHS P01 CA120964NCI NIH HHS P30 CA006516NCI NIH HHS R35 CA197588NCI NIH HHS R35 CA253097NIEHS NIH HHS P42 ES027707NIGMS NIH HHS K99 GM152834
6 · The paper itself

Abstract

Tyrosine phosphorylation of metabolic enzymes is an evolutionarily conserved posttranslational modification that facilitates rapid and reversible modulation of enzyme activity, localization, or function. Despite the high abundance of tyrosine phosphorylation events detected on metabolic enzymes in high-throughput mass spectrometry-based studies, functional characterization of tyrosine phosphorylation sites has been limited to a subset of enzymes. Since tyrosine phosphorylation is dysregulated across human diseases, including cancer, understanding the consequences of metabolic enzyme tyrosine phosphorylation events is critical for informing disease biology and therapeutic interventions. To globally identify metabolic enzyme tyrosine phosphorylation events and simultaneously assign functional significance to these sites, we performed parallel phosphoproteomics and polar metabolomics in nontumorigenic mammary epithelial cells (MCF10A) stimulated with epidermal growth factor (EGF) in the absence or presence of the EGF receptor inhibitor erlotinib. We performed an integrated analysis of the phosphoproteomic and metabolomic datasets to identify tyrosine phosphorylation sites on metabolic enzymes with functional consequences. We identified two previously characterized (pyruvate kinase muscle isozyme, phosphoglycerate mutase 1) and two uncharacterized (glutathione S-transferase Pi 1, glutamate dehydrogenase 1) tyrosine phosphorylation sites on metabolic enzymes with purported functions based on metabolomic analyses. We validated these hits using a doxycycline-inducible CRISPR interference system in MCF10A cells, in which target metabolic enzymes were depleted with simultaneous reexpression of wild-type, phosphomutant, or phosphomimetic isoforms. Together, these data provide a framework for identification, prioritization, and characterization of tyrosine phosphorylation sites on metabolic enzymes with functional significance.

Indexed as

MetabolomicsPhosphoproteinsProteomicsTyrosineCell LineEpidermal Growth FactorErlotinib HydrochlorideHumansPhosphoglycerate MutasePhosphorylationProteomeEpidermal Growth FactorErlotinib HydrochloridePhosphoglycerate MutasePhosphoproteinsProteomeTyrosinecancer metabolismEGFRmetabolomicsphosphotyrosineproteomics

Identifiers

PMID39536083
PMCPMC11588116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.